CellTrion

Anti-Arthritics/RheumaticsOncologyAsia-Pacific

CellTrion

Celltrion is a Korea-based biopharmaceutical company.

Celltrion is a Korea-based biopharmaceutical company.

Celltrion produce Remsima, the world first biosimilar mAb, approved in 2013 by EMA.  Remsima is a tumor necrosis factor a (TNF-a) antagonist used to treatrheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, adult Crohn's disease, plaque psoriasis, and psoriatic arthritis.

In Janaury 2014 it was announced that Celltrion’s cancer treatment biosimilar mAb trastuzumab biosimilar, Herzuma, has been approved in South Korea.           


Latest Articles

Parexel

Parexel

Back to top